Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
7/29/25 Eli Lilly (LLY) Jaypirca for Chronic Lymphocytic Leukemia (CLL)/Small Cell Lymphocytic Lymphoma (SLL) - NHL Subscribers Only Subscribers Only Subscribers Only
7/29/25 Aclaris Therapeutics (ACRS) ATI-2138 for Atopic Dermatitis (Eczema) Subscribers Only Subscribers Only Subscribers Only
7/28/25 Celcuity (CELC) gedatolisib for HR+/HER2- Breast Cancer Subscribers Only Subscribers Only Subscribers Only
7/25/25 Memo Therapeutics Potravitug for Antiviral - Other Treatments Subscribers Only Subscribers Only Subscribers Only
7/22/25 Replimune (REPL) vusolimogene oderparepvec for Melanoma Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
04/01/2025 Subscribers Only Subscribers Only Company - Divestment/Spinoff
04/24/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
01/01/2026 - 04/30/2025 Subscribers Only Subscribers Only Trial Announcement - Trial Completion (Emerging Markets)
05/20/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
05/22/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update